Austria In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry Genetic Testing, Haematology, Histology andCytolog...
each of the segments and sub-segments within market categories. Data from 2004 to 2011,forecast forward for 7 years to 201...
4.4.2 Urine Analysis, Revenue (2004-2018) 414.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry...
9.1 Infectious Immunology, Market Segmentation 1319.2 Infectious Immunology Market, Austria, Revenue Mix ($m), 2011 1329.3...
11.11 Qiagen N.V. 16711.11.1 Company Overview 16711.12 DiaSorin S.p.A 16711.12.1 Company Overview 16711.13 Gen-Probe Incor...
Assays 20813.1.7 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology S...
PCR Kit 23513.1.32 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 23613.1.33 Pressure BioSciences En...
25Table 5: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-201827Table 6: In Vitro Diagn...
Table 27: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 72Table 28: Haemostasi...
2011-2018 115Table 50: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011...
2011 158Table 72: Clinical Chemisty Market Pipeline Products 173Table 73: Immuno Chemistry Market Pipeline Products 176Tab...
Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus225Table 100: Immunexpress Ente...
24Figure 7: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-201826Figure 8: In Vitro Dia...
Forecast, 2011-2018 71Figure 34: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 73Fi...
Figure 58: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 118Figure ...
Figure 84: bioMerieux S.A., Company Share (%),Austria In Vitro Diagnostics Market, 2011 163Figure 85: Ortho-Clinical Diagn...
Upcoming SlideShare
Loading in …5
×

Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

205 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
205
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  1. 1. Austria In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry Genetic Testing, Haematology, Histology andCytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureReport Details:Published:December 2012No. of Pages: 264Price: Single User License – US$2500Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureSummaryGlobalData’s new report, “Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical ChemistryGenetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture” provides key market data on the Austria In VitroDiagnostics market. The report provides value (USD million), volume (units) and average price(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology AndCytology and Genetic Testing. The report also provides company shares and distribution sharesdata for each of the aforementioned market categories. The report is supplemented with globalcorporate-level profiles of the key market participants with information on company financials andpipeline products, wherever available.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts.Scope- Market size and company share data for In Vitro Diagnostics market categories – ImmunoChemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture,Histology And Cytology and Genetic Testing.- Annualized market revenues (USD million), volume (units) and average price (USD) data for
  2. 2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,forecast forward for 7 years to 2018.- 2011 company shares and distribution shares data for each of the market categories.- Global corporate-level profiles of key companies operating within the Austria In Vitro Diagnosticsmarket.- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, AbbottLaboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.Reasons to buy- Develop business strategies by identifying the key market categories and segments poised forstrong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the Austria In Vitro Diagnosticscompetitive landscape.- Develop capital investment strategies by identifying the key market segments expected toregister strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of productdistribution – Identify, understand and capitalize.Get your copy of this report @http://www.reportsnreports.com/reports/213277-austria-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-microbiology-culture.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 21.1 List of Tables 91.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In Austria 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, Austria, Company Share (2010-2011) 284 Clinical Chemistry In Austria 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 334.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 37
  3. 3. 4.4.2 Urine Analysis, Revenue (2004-2018) 414.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, Austria, Company Share (2010-2011) 465 Genetic Testing In Austria 485.1 Genetic Testing, Market Segmentation 485.2 Genetic Testing Market, Austria, Revenue Mix ($m), 2011 495.3 Genetic Testing Market, Austria, Segment Contribution (%), 2011 505.4 Genetic Testing Overall Revenue, (2004-2018) 515.5 Genetic Testing Distribution Share (2010-2011) 555.6 Genetic Testing, Austria, Company Share (2010-2011) 566 Haematology In Austria 586.1 Haematology Market, Market Segmentation 586.2 Haematology Market, Austria, Revenue Mix ($m), 2011 596.3 Haematology Market, Austria, Segment Contribution (%), 2011 606.4 Haematology Overall Revenue, (2004-2018) 616.4.1 Haematology Reagents, Revenue (2004-2018) 656.4.2 Immunohaematology, Revenue (2004-2018) 696.4.3 Haemostasis, Revenue (2004-2018) 736.4.4 Haematology Rapid Tests, Revenue (2004-2018) 776.4.5 Haematology Cell Counters, Revenue (2004-2018) 816.5 Haematology Distribution Share (2010-2011) 856.6 Haematology, Austria, Company Share (2010-2011) 867 Histology And Cytology In Austria 887.1 Histology and Cytology Market, Market Segmentation 887.2 Histology And Cytology Market, Austria, Revenue Mix ($m), 2011 897.3 Histology And Cytology Market, Austria, Segment Contribution (%), 2011 907.4 Histology And Cytology Overall Revenue, (2004-2018) 917.5 Histology And Cytology Distribution Share (2010-2011) 957.6 Histology And Cytology, Austria, Company Share (2010-2011) 968 Immuno Chemistry In Austria 988.1 Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011 988.2 Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 998.3 Immuno Chemistry Overall Revenue, (2004-2018) 1008.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 1048.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 1088.3.3 Endocrinology Tests, Revenue (2004-2018) 1128.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 1168.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 1208.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 1248.4 Immuno Chemistry Distribution Share (2010-2011) 1288.5 Immuno Chemistry, Austria, Company Share (2010-2011) 1299 Infectious Immunology In Austria 131
  4. 4. 9.1 Infectious Immunology, Market Segmentation 1319.2 Infectious Immunology Market, Austria, Revenue Mix ($m), 2011 1329.3 Infectious Immunology Market, Austria, Segment Contribution (%), 2011 1339.4 Infectious Immunology Overall Revenue, (2004-2018) 1349.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 1389.5 Infectious Immunology Distribution Share (2010-2011) 1429.6 Infectious Immunology, Austria, Company Share (2010-2011) 14310 Microbiology Culture In Austria 14510.1 Microbiology Culture, Market Segmentation 14510.2 Microbiology Culture Market, Austria, Revenue Mix ($m), 2011 14610.3 Microbiology Culture Market, Austria, Segment Contribution (%), 2011 14710.4 Microbiology Culture Overall Revenue, (2004-2018) 14810.4.1 Microbiology Analyzers, Revenue (2004-2018) 15210.5 Microbiology Culture Distribution Share (2010-2011) 15610.6 Microbiology Culture, Austria, Company Share (2010-2011) 15711 Overview of Key Companies in Austria In Vitro Diagnostics Market 15911.1 F. Hoffmann-La Roche Ltd. 15911.1.1 Company Overview 15911.1.2 Share in the Austria In Vitro Diagnostics Market 15911.2 Siemens Healthcare 16011.2.1 Company Overview 16011.2.2 Share in the Austria In Vitro Diagnostics Market 16011.3 Abbott Laboratories 16111.3.1 Company Overview 16111.3.2 Share in the Austria In Vitro Diagnostics Market 16111.4 Beckman Coulter, Inc. 16211.4.1 Company Overview 16211.4.2 Share in the Austria In Vitro Diagnostics Market 16211.5 bioMerieux S.A. 16311.5.1 Company Overview 16311.5.2 Share in the Austria In Vitro Diagnostics Market 16311.6 Ortho-Clinical Diagnostics Inc. 16411.6.1 Company Overview 16411.6.2 Share in the Austria In Vitro Diagnostics Market 16411.7 Bio-Rad Laboratories, Inc. 16511.7.1 Company Overview 16511.8 Sysmex Corporation 16511.8.1 Company Overview 16511.9 Alere Inc. 16611.9.1 Company Overview 16611.10 Becton, Dickinson and Company 16611.10.1 Company Overview 166
  5. 5. 11.11 Qiagen N.V. 16711.11.1 Company Overview 16711.12 DiaSorin S.p.A 16711.12.1 Company Overview 16711.13 Gen-Probe Incorporated 16811.13.1 Company Overview 16811.14 Danaher Corporation 16811.14.1 Company Overview 16811.15 Diagnostica Stago, Inc. 16911.15.1 Company Overview 16911.16 PerkinElmer, Inc. 16911.16.1 Company Overview 16911.17 Thermo Fisher Scientific Inc. 17011.17.1 Company Overview 17011.18 Horiba, Ltd. 17011.18.1 Company Overview 17011.19 Grifols, S.A. 17111.19.1 Company Overview 17111.20 Immucor, Inc. 17111.20.1 Company Overview 17111.21 Phadia AB 17211.21.1 Company Overview 17211.22 Life Technologies Corporation 17211.22.1 Company Overview 17212 In Vitro Diagnostics Market Pipeline Products 17312.1 Clinical Chemisty Market Pipeline Products 17312.2 Immuno Chemistry Market Pipeline Products 17612.3 Haematology Market Pipeline Products 18512.4 Infectious Immunology Market Pipeline Products 18712.5 Microbiology Culture Market Pipeline Products 19412.6 Histology And Cytology Market Pipeline Products 19512.7 Genetic Testing Market Pipeline Products 19613 Financial Deals Landscape 20113.1 Partnerships 20113.1.1 Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For TranscreenerEpigen Methyltransferase Assay 20113.1.2 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 20313.1.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 20513.1.4 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 20613.1.5 BioDot Enters Into Co-Marketing Agreement With JOT Automation 20713.1.6 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
  6. 6. Assays 20813.1.7 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology Solutions 20913.1.8 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpressDx Test 21113.1.9 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology21313.1.10 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 21413.1.11 CML HealthCare Enters Into Agreement With MaRS Innovation 21513.1.12 Akrivis Technologies Enters Into Co-Development Agreement With United StatesBiological 21613.1.13 Castle Biosciences Enters Into Licensing Agreement With Brigham and Womens HospitalFor Mesothelioma Test 21713.1.14 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 21813.1.15 GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 21913.1.16 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TBTest 22013.1.17 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 22113.1.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 22213.1.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 22313.1.20 Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers ForDNA-FISH Assays 22413.1.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus22513.1.22 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 22613.1.23 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POCTest 22713.1.24 One Lambda Enters Into Co-Marketing Agreement With CellTrend 22813.1.25 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics ForALK Cancer Biomarker 22913.1.26 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 23013.1.27 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker23113.1.28 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor CellTechnology 23213.1.29 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 23313.1.30 Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For VerigeneProducts 23413.1.31 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
  7. 7. PCR Kit 23513.1.32 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 23613.1.33 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 23713.1.34 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 23813.1.35 GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 23913.1.36 NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 24013.1.37 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 24113.1.38 Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT AssayFor Sepsis 24213.1.39 Roche Enters Into Co-Development Agreement With Technoclone 24313.1.40 Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 24413.1.41 Sony DADC Enters Into Co-Development Agreement With Axela 24613.1.42 Sony DADC BioSciences Enters Into Co-Development Agreement With MavenBiotechnologies 24714 Recent Developments 24814.1 Product News 24814.1.1 Sep 28, 2012: Anagnostics Announces Availability Of hybcell Pathogens DNA plexA AsCE-IVD Test 24814.1.2 Sep 27, 2011: Data From Evaluation Of Asuragen’s Signature LTx Leukemia Test To BePresented At Upcoming Planet XMAP In Vienna, Austria 24815 Appendix 24915.1 Definitions of Markets Covered in the Report 25015.1.1 In Vitro Diagnostics 25015.2 Research Methodology 26115.3 Secondary Research 26115.4 Primary Research 26215.5 Models 26215.6 Forecasts 26315.7 Expert Panels 26315.8 GlobalData Consulting 26315.9 Currency Conversion 26415.10 Contact Us 26415.11 Disclaimer 2641.1 List of TablesTable 1: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 19Table 2: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 21Table 3: In Vitro Diagnostics Market, Austria, Cross-Category Analysis, 2004-2018 23Table 4: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  8. 8. 25Table 5: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-201827Table 6: In Vitro Diagnostics, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 29Table 7: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 32Table 8: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 34Table 9: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 36Table 10: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 38Table 11: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 40Table 12: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 42Table 13: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 44Table 14: Clinical Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 45Table 15: Clinical Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 47Table 16: Genetic Testing Market, Austria, Segment Contribution (%), 2011 50Table 17: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 52Table 18: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 54Table 19: Genetic Testing, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 55Table 20: Genetic Testing, Austria, Company Share by Revenue ($m), USD Constant, 2010-201157Table 21: Haematology Market, Austria, Segment Contribution (%), 2011 60Table 22: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-201162Table 23: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-201864Table 24: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 66Table 25: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 68Table 26: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 70
  9. 9. Table 27: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 72Table 28: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 74Table 29: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 76Table 30: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 78Table 31: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 80Table 32: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 82Table 33: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 84Table 34: Haematology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-201185Table 35: Haematology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 87Table 36: Histology And Cytology Market, Austria, Segment Contribution (%), 2011 90Table 37: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 92Table 38: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 94Table 39: Histology And Cytology, Austria, Distribution Share by Revenue ($m), USD Constant,2010-2011 95Table 40: Histology And Cytology, Austria, Company Share by Revenue ($m), USD Constant,2010-2011 97Table 41: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 99Table 42: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 101Table 43: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 103Table 44: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 105Table 45: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 107Table 46: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 109Table 47: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 111Table 48: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 113Table 49: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
  10. 10. 2011-2018 115Table 50: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 117Table 51: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 119Table 52: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 121Table 53: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 123Table 54: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 125Table 55: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 127Table 56: Immuno Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011 128Table 57: Immuno Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011 130Table 58: Infectious Immunology Market, Austria, Segment Contribution (%), 2011 133Table 59: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 135Table 60: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 137Table 61: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 139Table 62: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 141Table 63: Infectious Immunology, Austria, Distribution Share by Revenue ($m), USD Constant,2010-2011 142Table 64: Infectious Immunology, Austria, Company Share by Revenue ($m), USD Constant,2010-2011 144Table 65: Microbiology Culture Market, Austria, Segment Contribution (%), 2011 147Table 66: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 149Table 67: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 151Table 68: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 153Table 69: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 155Table 70: Microbiology Culture, Austria, Distribution Share by Revenue ($m), USD Constant,2010-2011 156Table 71: Microbiology Culture, Austria, Company Share by Revenue ($m), USD Constant, 2010-
  11. 11. 2011 158Table 72: Clinical Chemisty Market Pipeline Products 173Table 73: Immuno Chemistry Market Pipeline Products 176Table 74: Haematology Market Pipeline Products 185Table 75: Infectious Immunology Market Pipeline Products 187Table 76: Microbiology Culture Market Pipeline Products 194Table 77: Histology And Cytology Market Pipeline Products 195Table 78: Genetic Testing Market Pipeline Products 196Table 79: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs ForTranscreener Epigen Methyltransferase Assay 201Table 80: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 203Table 81: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 205Table 82: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 206Table 83: BioDot Enters Into Co-Marketing Agreement With JOT Automation 207Table 84: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 208Table 85: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology Solutions 209Table 86: Med BioGene Amends Licensing Agreement With Precision Therapeutics ForLungExpress Dx Test 211Table 87: Ovizio Imaging Systems Enters Into Distribution Agreement With ApplikonBiotechnology 213Table 88: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 214Table 89: CML HealthCare Enters Into Agreement With MaRS Innovation 215Table 90: Akrivis Technologies Enters Into Co-Development Agreement With United StatesBiological 216Table 91: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 217Table 92: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 218Table 93: GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 219Table 94: Epistem Enters Into Distribution Agreement With Becton Dickinson For MycobacteriumTB Test 220Table 95: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 221Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 222Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test223Table 98: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis BiomarkersFor DNA-FISH Assays 224
  12. 12. Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus225Table 100: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 226Table 101: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4POC Test 227Table 102: One Lambda Enters Into Co-Marketing Agreement With CellTrend 228Table 103: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight GeneticsFor ALK Cancer Biomarker 229Table 104: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 230Table 105: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERGMarker 231Table 106: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating TumorCell Technology 232Table 107: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233Table 108: Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For VerigeneProducts 234Table 109: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen ForLongRange PCR Kit 235Table 110: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 236Table 111: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 237Table 112: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238Table 113: GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 239Table 114: NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 240Table 115: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 241Table 116: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCTAssay For Sepsis 242Table 117: Roche Enters Into Co-Development Agreement With Technoclone 243Table 118: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 244Table 119: Sony DADC Enters Into Co-Development Agreement With Axela 246Table 120: Sony DADC BioSciences Enters Into Co-Development Agreement With MavenBiotechnologies 2471.2 List of FiguresFigure 1: In Vitro Diagnostics, Market Segmentation 17Figure 2: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018 18Figure 3: In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011 20Figure 4: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011 21Figure 5: In Vitro Diagnostics Market Austria, Cross-Category Analysis, 2004-2018 22Figure 6: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  13. 13. 24Figure 7: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-201826Figure 8: In Vitro Diagnostics, Austria, Company Share (%), 2011 28Figure 9: Clinical Chemistry, Market Segmentation 30Figure 10: Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011 31Figure 11: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011 32Figure 12: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 33Figure 13: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 35Figure 14: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 37Figure 15: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 39Figure 16: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 41Figure 17: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 43Figure 18: Clinical Chemistry, Austria, Company Share (%), 2011 46Figure 19: Genetic Testing, Market Segmentation 48Figure 20: Genetic Testing Market, Austria, Revenue Mix ($m), 2011 49Figure 21: Genetic Testing Market, Austria, Segment Contribution (%), 2011 50Figure 22: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51Figure 23: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Figure 24: Genetic Testing, Austria, Company Share (%), 2011 56Figure 25: Haematology Market, Market Segmentation 58Figure 26: Haematology Market, Austria, Revenue Mix ($m), 2011 59Figure 27: Haematology Market, Austria, Segment Contribution (%), 2011 60Figure 28: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-201161Figure 29: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-201863Figure 30: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 65Figure 31: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 67Figure 32: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 69Figure 33: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment,
  14. 14. Forecast, 2011-2018 71Figure 34: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 73Figure 35: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 75Figure 36: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 77Figure 37: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 79Figure 38: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 81Figure 39: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 83Figure 40: Haematology, Austria, Company Share (%), 2011 86Figure 41: Histology and Cytology Market, Market Segmentation 88Figure 42: Histology And Cytology Market, Austria, Revenue Mix ($m), 2011 89Figure 43: Histology And Cytology Market, Austria, Segment Contribution (%), 2011 90Figure 44: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 91Figure 45: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 93Figure 46: Histology And Cytology, Austria, Company Share (%), 2011 96Figure 47: Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011 98Figure 48: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011 99Figure 49: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 100Figure 50: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 102Figure 51: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 104Figure 52: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 106Figure 53: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 108Figure 54: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 110Figure 55: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 112Figure 56: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 114Figure 57: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 116
  15. 15. Figure 58: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 118Figure 59: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 120Figure 60: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 122Figure 61: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 124Figure 62: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 126Figure 63: Immuno Chemistry, Austria, Company Share (%), 2011 129Figure 64: Infectious Immunology, Market Segmentation 131Figure 65: Infectious Immunology Market, Austria, Revenue Mix ($m), 2011 132Figure 66: Infectious Immunology Market, Austria, Segment Contribution (%), 2011 133Figure 67: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 134Figure 68: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 136Figure 69: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Figure 70: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 20011-2018 140Figure 71: Infectious Immunology, Austria, Company Share (%), 2011 143Figure 72: Microbiology Culture, Market Segmentation 145Figure 73: Microbiology Culture Market, Austria, Revenue Mix ($m), 2011 146Figure 74: Microbiology Culture Market, Austria, Segment Contribution (%), 2011 147Figure 75: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 148Figure 76: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 150Figure 77: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 152Figure 78: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 154Figure 79: Microbiology Culture, Austria, Company Share (%), 2011 157Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Austria In Vitro Diagnostics Market,2011 159Figure 81: Siemens Healthcare, Company Share (%),Austria In Vitro Diagnostics Market, 2011160Figure 82: Abbott Laboratories, Company Share (%),Austria In Vitro Diagnostics Market, 2011 161Figure 83: Beckman Coulter, Inc., Company Share (%),Austria In Vitro Diagnostics Market, 2011162
  16. 16. Figure 84: bioMerieux S.A., Company Share (%),Austria In Vitro Diagnostics Market, 2011 163Figure 85: Ortho-Clinical Diagnostics Inc., Company Share (%),Austria In Vitro DiagnosticsMarket, 2011 164Contact: sales@reportsandreports.com for more information.

×